Aarti Drugs Ltd

Aarti Drugs Limited will hold a board meeting on Thursday, August 27, 2026, to consider and approve the “Aarti Drugs Limited – Performance Stock Option Plan 2026,” and the trading window for the company will be closed from August 25, 2026, until August 29, 2026, in accordance with SEBI regulations.

Aarti Drugs Limited will hold a board meeting on Thursday, August 27, 2026, to consider and approve the “Aarti Drugs Limited – Performance Stock Option Plan 2026,” and the trading window for the company will be closed from August 25, 2026, until August 29, 2026, in accordance with SEBI regulations.

Aarti Drugs Limited (NSE: AARTIDRUGS; BSE:524348) announced consolidated financial results for the quarter ended June 30, 2026, reporting total revenue of Rs 703.6 crore, a 19% year-over-year increase compared to Rs 590.8 crore in the prior year’s corresponding quarter. The company’s EBITDA rose to Rs 96.9 crore, a 30% increase year-over-year, with an EBITDA margin expansion of 120 basis points to 13.8%, while profit after tax stood at Rs 50.1 crore. Aarti Drugs’ Chief Financial Officer and Chief Operating Officer, Adhish Patil, noted a recovery in pricing environments and emphasized ongoing investments in capacity enhancement and backward integration, including expansion of oral solid dosage capabilities in Baddi, Himachal Pradesh.

Aarti Drugs Limited announced leadership changes effective October 1, 2026, with Shri Rashesh C. Gogri being elevated to Chairman in addition to his role as Managing Director, and Shri Adhish P. Patil appointed as Managing Director, subject to shareholder approval. Current Chairman, Managing Director and CEO Shri Prakash M. Patil will step down from his executive responsibilities at the close of business hours on September 30, 2026, and will continue to provide guidance and support during the transition. The changes, recommended by the Nomination and Remuneration Committee, are aimed at strengthening governance and ensuring long-term strategic growth for the Mumbai-based API pharmaceutical company, which is part of the $6 billion Aarti Group of Industries.

Aarti Drugs Ltd share price gained 2.64% to Rs 423.5. The Company's net profit softened by 9.28% to Rs 50.13 crore, while revenue from operations eased by 2.43% to Rs 702.78 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, gaining 5.88%. It has improved by 2.79% over last one week and rallied by 15.59% in last one month while the market capitalization of Aarti Drugs Ltd has marginally improved by 4.66% and 12.92% in the same period respectively. Profit before tax (PBT) of Aarti Drugs Ltd stood at Rs 69.24 crore in Q2 FY26, expanding by 35.47% year-on-year, and slipping 1.59% quarter-on-quarter. EBITDA came in at Rs 97 crore, surging by 32.02% YoY and rising 2.47% sequentially. Total expenses slightly declined by 3.03% to Rs 623.04 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 469.35 crore, posting a minor increase of 9.87% YoY, while employee benefits expense was at Rs 36.51 crore, surging 13.10% YoY. For the TTM ended FY26, revenue from operations declined slightly by 5.60% to Rs 2387.03 crore, while net profit slipped by 2.03% to Rs 168.1 crore, compared to previous TTM. EBITDA jumped by 31576% to Rs 270.7 crore, and PBT contracted 10.08% to Rs 211.77 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 244.58 crore in FY26, as against Rs 358.92 crore in FY25. Aarti Drugs Ltd crashed 21.03% in last one year, underperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.

Aarti Drugs Limited announced several leadership changes effective October 1, 2026, pending shareholder approval where applicable. Prakash M. Patil will retire as Chairman, with Rashesh C. Gogri assuming the role in addition to his current position as Managing Director. Adish P. Patil has been appointed as Managing Director for a five-year term. Additionally, Nilesh B. Patil will join as a Whole-time Director, while Harshit M. Savla, Harit P. Shah, Hasmukh B. Dedhia, Ajit E. Venugopalan, and Sandeep M. Joshi are being re-appointed. Brief profiles and relationship disclosures for the appointed and re-appointed directors are included in the filing.

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Net profit of Aarti Drugs declined 12.20% to Rs 55.19 crore in the quarter ended March 2026 as against Rs 62.86 crore during the previous quarter ended March 2025. Sales rose 6.43% to Rs 720.30 crore in the quarter ended March 2026 as against Rs 676.76 crore during the previous quarter ended March 2025. For the full year,net profit rose 15.91% to Rs 194.92 crore in the year ended March 2026 as against Rs 168.16 crore during the previous year ended March 2025. Sales rose 7.47% to Rs 2565.31 crore in the year ended March 2026 as against Rs 2387.03 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales720.30676.76 6 2565.312387.03 7 OPM %13.3013.79 -12.0512.03 - PBDT88.4086.04 3 277.87267.55 4 PBT70.3671.16 -1 210.90211.77 0 NP55.1962.86 -12 194.92168.16 16 Powered by Capital Market - Live

Net profit of Aarti Drugs declined 26.87% to Rs 44.96 crore in the quarter ended March 2026 as against Rs 61.48 crore during the previous quarter ended March 2025. Sales rose 1.40% to Rs 631.68 crore in the quarter ended March 2026 as against Rs 622.96 crore during the previous quarter ended March 2025. For the full year,net profit rose 7.57% to Rs 169.22 crore in the year ended March 2026 as against Rs 157.31 crore during the previous year ended March 2025. Sales rose 3.99% to Rs 2260.39 crore in the year ended March 2026 as against Rs 2173.65 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales631.68622.96 1 2260.392173.65 4 OPM %12.5514.23 -11.5412.08 - PBDT73.5282.88 -11 236.95246.54 -4 PBT58.5770.67 -17 181.31198.75 -9 NP44.9661.48 -27 169.22157.31 8 Powered by Capital Market - Live

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 15 May 2026.